A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Koreth, John, Kim, Haesook T., Lange, Paulina B., Bindra, Bhavjot, Reynolds, Carol G., Chammas, Marie J., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Nikiforow, Sarah, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/
https://ncbi.nlm.nih.gov/pubmed/26055298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados